Anthony Christopher Vernon - Publications

Affiliations: 
King's College (London), London, England, United Kingdom 
Area:
Neuroscience, schizophrenia, parkinson's disease

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Vernon AC, So PW, Lythgoe DJ, Chege W, Cooper JD, Williams SC, Kapur S. Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26475576 DOI: 10.1016/j.euroneuro.2015.09.022  0.48
2015 Cotel MC, Lenartowicz EM, Natesan S, Modo MM, Cooper JD, Williams SC, Kapur S, Vernon AC. Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26321204 DOI: 10.1016/j.euroneuro.2015.08.004  0.48
2015 Harrison IF, Crum WR, Vernon AC, Dexter DT. Neurorestoration Induced by the HDAC Inhibitor Sodium Valproate in the Lactacystin Model of Parkinson's is Associated with Histone Acetylation and Upregulation of Neurotrophic Factors. British Journal of Pharmacology. PMID 26040297 DOI: 10.1111/bph.13208  0.48
2015 Turkheimer FE, Leech R, Expert P, Lord LD, Vernon AC. The brain's code and its canonical computational motifs. From sensory cortex to the default mode network: A multi-scale model of brain function in health and disease. Neuroscience and Biobehavioral Reviews. 55: 211-22. PMID 25956253 DOI: 10.1016/j.neubiorev.2015.04.014  0.48
2014 Finlay CJ, Duty S, Vernon AC. Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Frontiers in Neurology. 5: 95. PMID 24971074 DOI: 10.3389/fneur.2014.00095  0.48
2014 Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, Cooper JD, Williams SC, Kapur S. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biological Psychiatry. 75: 982-90. PMID 24143881 DOI: 10.1016/j.biopsych.2013.09.012  0.48
2013 Vernon AC, Hajek T. Effects of lithium on magnetic resonance imaging signal might not preclude increases in brain volume after chronic lithium treatment Biological Psychiatry. 74. PMID 23998561 DOI: 10.1016/j.biopsych.2012.12.028  0.48
2013 Crum WR, Modo M, Vernon AC, Barker GJ, Williams SC. Registration of challenging pre-clinical brain images. Journal of Neuroscience Methods. 216: 62-77. PMID 23558335 DOI: 10.1016/j.jneumeth.2013.03.015  0.48
2012 Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, Kapur S. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biological Psychiatry. 71: 855-63. PMID 22244831 DOI: 10.1016/j.biopsych.2011.12.004  0.48
2012 Vernon AC, Modo M. Do levodopa treatments modify the morphology of the parkinsonian brain? Movement Disorders. 27: 166-167. PMID 22076912 DOI: 10.1002/mds.24018  0.48
2011 Vernon AC, Smith EJ, Stevanato L, Modo M. Selective activation of metabotropic glutamate receptor 7 induces inhibition of cellular proliferation and promotes astrocyte differentiation of ventral mesencephalon human neural stem/progenitor cells. Neurochemistry International. 59: 421-31. PMID 21624409 DOI: 10.1016/j.neuint.2011.04.001  0.48
2011 Vernon AC, Crum WR, Johansson SM, Modo M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. Plos One. 6: e17269. PMID 21364887 DOI: 10.1371/journal.pone.0017269  0.48
2011 Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation Biological Psychiatry. 69: 936-944. PMID 21195390 DOI: 10.1016/j.biopsych.2010.11.010  0.48
2010 Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT. Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease. Parkinson's Disease. 2010. PMID 20948891 DOI: 10.4061/2010/190450  0.48
2010 Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of ?-synuclein neuropathology required and feasible? Brain Research Reviews. 65: 28-55. PMID 20685363 DOI: 10.1016/j.brainresrev.2010.05.006  0.48
2010 Vernon AC, Johansson SM, Modo MM. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. Bmc Neuroscience. 11: 1. PMID 20051106 DOI: 10.1186/1471-2202-11-1  0.48
2009 Vernon AC. Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease Journal of Neuroscience. 29: 12842-12844. PMID 19828798 DOI: 10.1523/JNEUROSCI.4156-09.2009  0.48
2008 Vernon AC, Croucher MJ, Dexter DT. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. Neuroreport. 19: 475-8. PMID 18287950 DOI: 10.1097/WNR.0b013e3282f602df  0.48
2007 Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. Journal of Neurochemistry. 103: 1075-91. PMID 17714448 DOI: 10.1111/j.1471-4159.2007.04860.x  0.48
2007 Vernon AC, Zbarsky V, Datla KP, Dexter DT, Croucher MJ. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. The Journal of Pharmacology and Experimental Therapeutics. 320: 397-409. PMID 17012606 DOI: 10.1124/jpet.106.108159  0.48
Show low-probability matches.